ClinicalTrials.gg
CompletedNCT01488071REVIVEUpdated Mar 26, 2014Results posted

A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication

A Phase 3 interventional study of Vortioxetine (Lu AA21004) and Agomelatine in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-03-26.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
495
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
20th of 54
495 · median 413
Started
2012
with 2 others
Phase 3
31 of 54
1 open now
Registered
22nd of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 20th largest by enrollment, is one of 3 that started in 2012, is one of 31 in phase 3, and was the 22nd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin Reuptake Inhibitors (SRI) antidepressants.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Multimodal antidepressant
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is being treated with a serotonin reuptake inhibitor (SRI) antidepressant (monotherapy) that was prescribed to treat Major Depressive Episode ( criteria)
  • The response to the current SRI treatment is inadequate and patient agrees to discontinue the current SRI at the baseline
  • Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥22 at the Screening Visit and Baseline
  • The patient, if a woman, must: agree not to try to become pregnant during the study, AND use adequate, highly effective

Exclusion criteria

Exclusion Criteria:

  • The patient has any current Axis I disorders ( criteria) other than Major Depressive Disorder (MDD), General Anxiety Disorder (GAD) and Social Anxiety Disorder (SAD)
  • The patient is at significant risk of suicide
  • The patient is currently receiving formal psychotherapy or other psychoactive medications

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
495 participants (actual)

Study arms

  • Experimental
    Vortioxetine 10 mg or 20 mg

    Drug: Vortioxetine (Lu AA21004)

  • Active comparator
    Agomelatine 25 mg or 50 mg

    Drug: Agomelatine

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in MADRS Total Score at Week 8

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline in MADRS Total Score at Week 12

    Time frame: Baseline and Week 12

  2. Change From Baseline in HAM-A Total Score at Week 8

    The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56; higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline and Week 8

  3. Change From Baseline in HAM-A Total Score at Week 12

    Time frame: Baseline and Week 12

  4. Change From Baseline in CGI-S Score at Week 8

    The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating. Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline and Week 8

  5. Change From Baseline in CGI-S Score at Week 12

    Time frame: Baseline and Week 12

  6. Change in Clinical Status Using CGI-I Score at Week 8

    The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment. Higher score = more affected.

    Time frame: Week 8

  7. Change in Clinical Status Using CGI-I Score at Week 12

    Time frame: Week 12

  8. Proportion of Patients Who Respond at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)

    Time frame: Baseline and Week 8

  9. Proportion of Patients Who Respond at Week 12 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)

    Time frame: Baseline and Week 12

  10. Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score <=10)

    Time frame: Week 8

  11. Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score <=10)

    Time frame: Week 12

  12. Change From Baseline in SDS Total Score at Week 8

    The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

    Time frame: Baseline and Week 8

  13. Change From Baseline in SDS Total Score at Week 12

    Time frame: Baseline and Week 12

07

Results

Posted Mar 26, 2014

Participant flow

In- or outpatients who had been treated with antidepressant selective serotonin reuptake inhibitor (SSRI) or selective noradrenaline reuptake inhibitor (SNRI) monotherapy that was prescribed to treat a single episode of Major Depressive Disorder (MDD) or recurrent MDD.

Participant flow — Overall Study
MilestoneVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Started253242
Completed200179
Not completed5363
Withdrew: Adverse event1523
Withdrew: Lack of efficacy1117
Withdrew: Non-compliance with study drug20
Withdrew: Protocol violation57
Withdrew: Withdrawal of consent1412
Withdrew: Lost to follow-up10
Withdrew: Administrative or other reason(s)54

Outcome measures

PrimaryChange From Baseline in MADRS Total Score at Week 8

The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in MADRS Total Score at Week 8
units on a scaleVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Change From Baseline in MADRS Total Score at Week 8-16.53 ± 0.48-14.38 ± 0.51
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Mixed Models Analysis · p = 0.0018 (Under established non-inferiority the p-value is not adjusted.) · Mean difference (final values): -2.16 · 95% CI -3.51 to -0.81MMRM
SecondaryChange From Baseline in MADRS Total Score at Week 12
Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in MADRS Total Score at Week 12
units on a scaleVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Change From Baseline in MADRS Total Score at Week 12-18.95 ± 0.50-16.92 ± 0.53
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Mixed Models Analysis · p = 0.0054 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -2.03 · 95% CI -3.45 to -0.60The same MMRM methodology as for the primary endpoint was used.
SecondaryChange From Baseline in HAM-A Total Score at Week 8

The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56; higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in HAM-A Total Score at Week 8
units on a scaleVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Change From Baseline in HAM-A Total Score at Week 8-11.68 ± 0.39-9.79 ± 0.42
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Mixed Models Analysis · p = 0.0008 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -1.89 · 95% CI -2.98 to -0.80The same MMRM methodology as for the primary endpoint was used.
SecondaryChange From Baseline in HAM-A Total Score at Week 12
Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in HAM-A Total Score at Week 12
units on a scaleVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Change From Baseline in HAM-A Total Score at Week 12-13.52 ± 0.40-11.59 ± 0.42
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Mixed Models Analysis · p = 0.0007 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -1.93 · 95% CI -3.04 to -0.81The same MMRM methodology as for the primary endpoint was used.
SecondaryChange From Baseline in CGI-S Score at Week 8

The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating. Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in CGI-S Score at Week 8
units on a scaleVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Change From Baseline in CGI-S Score at Week 8-1.84 ± 0.07-1.55 ± 0.07
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Mixed Models Analysis · p = 0.0023 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -0.30 · 95% CI -0.48 to -0.11The same MMRM methodology as for the primary endpoint was used.
SecondaryChange From Baseline in CGI-S Score at Week 12
Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in CGI-S Score at Week 12
units on a scaleVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Change From Baseline in CGI-S Score at Week 12-2.20 ± 0.07-1.93 ± 0.07
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Mixed Models Analysis · p = 0.0075 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -0.27 · 95% CI -0.47 to -0.07The same MMRM methodology as for the primary endpoint was used.
SecondaryChange in Clinical Status Using CGI-I Score at Week 8

The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment. Higher score = more affected.

Time frame:
Week 8
Reported as:
Mean · units on a scale
Change in Clinical Status Using CGI-I Score at Week 8
units on a scaleVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Change in Clinical Status Using CGI-I Score at Week 81.97 ± 0.062.22 ± 0.07
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Mixed Models Analysis · p = 0.0048 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -0.25 · 95% CI -0.42 to -0.08The same MMRM methodology as for the primary endpoint was used.
SecondaryChange in Clinical Status Using CGI-I Score at Week 12
Time frame:
Week 12
Reported as:
Mean · units on a scale
Change in Clinical Status Using CGI-I Score at Week 12
units on a scaleVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Change in Clinical Status Using CGI-I Score at Week 121.74 ± 0.061.99 ± 0.07
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Mixed Models Analysis · p = 0.0055 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -0.25 · 95% CI -0.42 to -0.07The same MMRM methodology as for the primary endpoint was used.
SecondaryProportion of Patients Who Respond at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Proportion of Patients Who Respond at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
percentage of participantsVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Proportion of Patients Who Respond at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)61.547.3
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Regression, Logistic · p = 0.0012 (Wald's Test. No adjustments for multiple comparisons were made.) · Odds ratio (or): 1.81 · 95% CI 1.26 to 2.60
SecondaryProportion of Patients Who Respond at Week 12 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Proportion of Patients Who Respond at Week 12 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)
percentage of participantsVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Proportion of Patients Who Respond at Week 12 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline)69.856.0
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Regression, Logistic · p = 0.0014 (Wald's Test. No adjustments for multiple comparisons were made.) · Odds ratio (or): 1.83 · 95% CI 1.26 to 2.65
SecondaryProportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score <=10)
Time frame:
Week 8
Reported as:
Number · percentage of participants
Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score <=10)
percentage of participantsVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score <=10)40.529.5
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Regression, Logistic · p = 0.0054 (Wald's Test. No adjustments for multiple comparisons were made.) · Odds ratio (or): 1.72 · 95% CI 1.17 to 2.52
SecondaryProportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score <=10)
Time frame:
Week 12
Reported as:
Number · percentage of participants
Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score <=10)
percentage of participantsVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score <=10)55.239.4
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Regression, Logistic · p = 0.0002 (Wald's Test. No adjustments for multiple comparisons were made.) · Odds ratio (or): 2.01 · 95% CI 1.39 to 2.90
SecondaryChange From Baseline in SDS Total Score at Week 8

The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline in SDS Total Score at Week 8
units on a scaleVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Change From Baseline in SDS Total Score at Week 8-9.28 ± 0.53-7.06 ± 0.55
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Mixed Models Analysis · p = 0.0021 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -2.22 · 95% CI -3.63 to -0.81The same MMRM methodology as for the primary endpoint was used.
SecondaryChange From Baseline in SDS Total Score at Week 12
Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in SDS Total Score at Week 12
units on a scaleVortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mg
Change From Baseline in SDS Total Score at Week 12-10.99 ± 0.55-9.24 ± 0.58
Statistical analysis
  • Vortioxetine 10 mg or 20 mg vs Agomelatine 25 mg or 50 mg · Mixed Models Analysis · p = 0.0209 (No adjustments for multiple comparisons were made.) · Mean difference (final values): -1.75 · 95% CI -3.23 to -0.27The same MMRM methodology as for the primary endpoint was used.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine—3/253 (1.2%)82/253 (32.4%)
Agomelatine—4/242 (1.7%)77/242 (31.8%)
Most frequent serious events
Most frequent serious events
EventVortioxetineAgomelatine
MetrorrhagiaReproductive system and breast disorders0/1951/175
Gamma-glutamyltransferase increasedInvestigations0/2531/242
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2531/242
Social stay hospitalisationSocial circumstances0/2531/242
Peptic ulcer perforationGastrointestinal disorders1/2530/242
Oedema peripheralGeneral disorders1/2530/242
AnxietyPsychiatric disorders1/2530/242
DepressionPsychiatric disorders1/2530/242
Most frequent other events
Most frequent other events
EventVortioxetineAgomelatine
NauseaGastrointestinal disorders41/25322/242
HeadacheNervous system disorders26/25332/242
DizzinessNervous system disorders18/25328/242
SomnolenceNervous system disorders10/25319/242

Baseline characteristics

Age and Gender: All-patients-treated set (APTS) - all patients in the APRS who took at least one dose of investigational medicinal product (IMP). Study Specific Characteristics: Full-analysis set (FAS) - all patients in the APTS who had a valid baseline assessment and at least one valid post-baseline assessment of the MADRS total score.

Age, Continuous
Age, Continuous(years)Vortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mgTotal
Mean47.0 ± 12.445.6 ± 12.446.3 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mgTotal
Female195175370
Male5867125
MADRS: Baseline Total Score
MADRS: Baseline Total Score(units on a scale)Vortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mgTotal
Mean29.1 ± 4.428.7 ± 4.028.9 ± 4.2
HAM-A: Baseline Total Score
HAM-A: Baseline Total Score(units on a scale)Vortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mgTotal
Mean21.6 ± 6.321.4 ± 6.221.5 ± 6.2
CGI-S Baseline Severity Score
CGI-S Baseline Severity Score(units on a scale)Vortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mgTotal
Mean4.4 ± 0.64.4 ± 0.64.4 ± 0.6
SDS Total Baseline Score
SDS Total Baseline Score(units on a scale)Vortioxetine 10 mg or 20 mgAgomelatine 25 mg or 50 mgTotal
Mean19.2 ± 5.319.3 ± 5.219.3 ± 5.3
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. J Psychiatr Res. 2018 Jun;101:72-79. doi: 10.1016/j.jpsychires.2018.02.017. Epub 2018 Feb 22. PubMed 29554497 ↗
  • Montgomery SA, Nielsen RZ, Poulsen LH, Haggstrom L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014 Sep;29(5):470-82. doi: 10.1002/hup.2424. PubMed 25087600 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012 and a primary completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2011
First posted
Dec 8, 2011
Start
Jan 2012
Primary completionActual
Dec 2012
Results first posted
Mar 26, 2014
Last update
Mar 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01488071
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Dec 8, 2011
Start date
Jan 2012
Primary completion
Dec 2012
Results posted
Mar 26, 2014
Last update
Mar 26, 2014

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion